6-Mercaptopurine Nucleoside Analogues

JP7576843B2Active Publication Date: 2024-11-01リャオシビン
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
JP2021521261
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-10-17
Filing Date
2019-10-16
Publication Date
2024-11-01
Estimated Expiration
2039-10-16

Smart Images

  • Figure 0007576843000001
    Figure 0007576843000001
  • Figure 0007576843000002
    Figure 0007576843000002
  • Figure 0007576843000003
    Figure 0007576843000003
Patent Text Reader

Abstract

The compound has the following formula (I) or formula (II), an isomer thereof, a tautomer thereof, a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable prodrug thereof: [Case 1] TIFF2022512751000045.tif39168
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application claims priority to U.S. Provisional Application No. 62 / 746,701, filed October 17, 2018, which is incorporated by reference for all purposes as if fully set forth herein.

[0002] FIELD OF THEINVENTION The present invention relates to 6-mercaptopurine nucleoside analogs for the treatment of various diseases, such as cancer and viral infections. [Background technology]

[0003] 2. Background of the Invention Nucleoside analogs are effective in treating a variety of diseases, including cancer and viral infections, such as herpes simplex virus (HSV), human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). Nucleoside analogs are also used to selectively target telomerase activity. Most normal cells lack telomerase activity.

[0004] Many nucleoside analogs are commercially available as therapeutic agents for cancer and viral infections. After entering cells, nucleoside analogs are activated by nucleoside and nucleotide kinases to form phosphorylated nucleoside analogs. The phosphorylated nucleoside analogs exert their therapeutic effects. Summary of the Invention [Problem to be solved by the invention]

[0005] However, nucleoside analog drugs have several drawbacks. Phosphorylation of nucleoside analogs is often inefficient. Nucleoside analogs have low oral bioavailability due to poor intestinal permeability. Resistance to some nucleoside analogs has developed. To overcome these limitations, effective and bioavailable nucleoside analogs are needed. [Means for solving the problem]

[0006] Summary of the Invention The present invention provides a compound having the following formula (I), an isomer thereof, a tautomer thereof, a pharma- ceutically acceptable solvate thereof, or a pharma- ceutically acceptable prodrug thereof: [ka]

[0007] In formula (I), X 1 is -O- or -NH-, R 7 is -H, alkyl, alkyl substituted with one or more -OH or halo groups, alkenyl, alkenyl substituted with one or more -OH or halo groups, alkynyl, alkynyl substituted with one or more -OH or halo groups, cycloalkyl, cycloalkyl substituted with one or more -OH or halo groups, aryl, one or more of -OH, halo, -CN, -NO 2 , aryl substituted with alkyl, alkoxy or haloalkyl groups, benzyl, one or more of -OH, halo, -CN, -NO 2 , benzyl substituted with alkyl, alkoxy or haloalkyl groups, heteroaryl, one or more of -OH, halo, -CN, -NO 2 , heteroaryl substituted with alkyl, alkoxy or haloalkyl groups, heterocyclyl, one or more of -OH, halo, -CN, -NO 2 , heterocyclyl substituted with alkyl, alkoxy or haloalkyl groups, -CH(CH 3 )COOCH(CH 3 ) 2 , [ka] or [ka] and R4 -H, -OH, -CH 3 , -Cl, -F, -N 3 , -OCH 3 , alkenyl, or alkynyl; R 5 -H, -OH, -CH 3 , -Cl, -F, -N 3 , -OCH 3 , alkenyl, or alkynyl; R 10 is -LM, where L is -O-, -O-CH 2 -, -S-, -NH-, -CO-, -SO-, or -CH 2 -, M is alkyl, alkyl substituted with one or more -OH or halo groups, alkenyl, alkenyl substituted with one or more -OH or halo groups, alkynyl, alkynyl substituted with one or more -OH or halo groups, alkoxy, alkoxy substituted with one or more -OH or halo groups, cycloalkyl, cycloalkyl substituted with one or more -OH or halo groups, aryl, one or more of -OH, halo, -CN, -NO 2 , aryl substituted with alkyl, alkoxy or haloalkyl groups, benzyl, one or more of -OH, halo, -CN, -NO 2 , benzyl substituted with alkyl, alkoxy or haloalkyl groups, heteroaryl, one or more of -OH, halo, -CN, -NO 2 , heteroaryl, heterocyclyl substituted with alkyl, alkoxy or haloalkyl groups, or one or more of -OH, halo, -CN, -NO 2 , heterocyclyl substituted with an alkyl, alkoxy, or haloalkyl group.

[0008] In another embodiment, in formula (I): X 1 is -O-, R 7 teeth, [ka] or [ka] and R 4 is -H, R 5 is -H, R 10 is -LM, where L is -O- or -O-CH 2 -, M is alkynyl, alkynyl substituted with one or more -OH or halo groups, aryl, one or more -OH, halo, -CN, -NO 2 , aryl substituted with alkyl, alkoxy or haloalkyl groups, benzyl, one or more of -OH, halo, -CN, -NO 2 , benzyl substituted with alkyl, alkoxy or haloalkyl groups, heterocyclyl, or one or more of -OH, halo, -CN, -NO 2 , heterocyclyl substituted with an alkyl, alkoxy or haloalkyl group.

[0009] In another embodiment, the compound of formula (I) is 2-amino-9-(((2S,4aR,6R,7aS)-2-(((4R,5R)-5-(benzyloxy)-1,2-dithian-4-yl)oxy)-2-oxidetetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-6-yl)-1,9-dihydro-6H-purine-6-thione, 2-amino-9-((2S,4aR,6R,7aS)-2-(((4S,5S)-5-(benzyloxy)-1,2-dithian-4-yl)oxy)-2-oxidetetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-6-yl)-1,9-dihydro-6H-purine-6-thione, 2-amino-9-((2R,4aR,6R,7aS)-2-(((4S,5S)-5-(benzyloxy)-1,2-dithian-4-yl)oxy-2-oxidetetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-6-yl]-1,9-dihydro-6H-purine-6-thione, 2-amino-9-((2R,4aR,6R,7aS)-2-(((4R,5R)-5-(benzyloxy)-1,2-dithian-4-yl)oxy)-2-oxidetetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-6-yl)-1,9-dihydro-6H-purine-6-thione, S-(3-(((2R,4aR,6R,7aS)-6-(2-amino-6-thioxo-1,6-dihydro-9H-purin-9-yl)-2-oxidetetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-2-yl)oxy)propyl)2,2-dimethyl-3-propoxypropanethioate, S-(3-(((2S,4aR,6R,7aS)-6-(2-amino-6-thioxo-1,6-dihydro-9H-purin-9-yl)-2-oxidetetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-2-yl)oxy)propyl)2,2-dimethyl-3-propoxypropanethioate, 2-amino-9-((2S,4aR,6R,7aS)-2-(((4R,5R)-5-(benzyloxy)-1,2-dithian-4-yl)oxy)-2-sulfidotetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-6-yl)-1,9-dihydro-6H-purine-6-thione, 2-amino-9-((2R,4aR,6R,7aS)-2-(((4R,5R)-5-((2-methylbenzyl)oxy)-1,2-dithian-4-yl)oxy)-2-oxidetetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-6-yl)-1,9-dihydro-6H-purine-6-thione, 2-amino-9-((2R,4aR,6R,7aS)-2-oxido-2-(((4R,5R)-5-(prop-2-yn-1-yloxy)-1,2-dithian-4-yl)oxy)tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-6-yl)-1,9-dihydro-6H-purine-6-thione, 2-amino-9-((2R,4aR,6R,7aS)-2-(((4R,5R)-5-methoxy-1,2-dithian-4-yl)oxy)-2-oxidetetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-6-yl)-1,9-dihydro-6H-purine-6-thione, and 2-amino-9-((2R,4aR,6R,7aS)-2-oxido-2-(((4R,5R)-5-(pyridin-4-ylmethoxy)-1,2-dithian-4-yl)oxy)tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-6-yl)-1,9-dihydro-6H-purine-6-thione.

[0010] In one embodiment, the present application provides a compound having the following formula (II), an isomer thereof, a tautomer thereof, a pharma- ceutically acceptable solvate thereof, or a pharma- ceutically acceptable prodrug thereof: [ka] In formula (II), X 2 is -O- or -NH-, X 3 is -O- or -NH-, X 4 -CH 2、 or nil, Y is -O-, -S-, or SO 2 - and R 8 and R 9 is -H, alkyl, alkyl substituted with one or more -OH or halo groups, alkenyl, alkenyl substituted with one or more -OH or halo groups, alkynyl, alkynyl substituted with one or more -OH or halo groups, cycloalkyl, cycloalkyl substituted with one or more -OH or halo groups, aryl, one or more of -OH, halo, -CN, -NO 2 , aryl substituted with alkyl, alkoxy or haloalkyl groups, benzyl, one or more of -OH, halo, -CN, -NO 2, benzyl substituted with alkyl, alkoxy or haloalkyl groups, heteroaryl, one or more of -OH, halo, -CN, -NO 2 , heteroaryl substituted with alkyl, alkoxy or haloalkyl groups, heterocyclyl, one or more of -OH, halo, -CN, -NO 2 , heterocyclyl substituted with alkyl, alkoxy or haloalkyl groups, -CH(CH 3 )COOCH(CH 3 ) 2 , [ka] [ka] and, [ka] or R 8 and R 9 is a 5- or 6-membered heterocyclic ring or one or more of -OH, halo, -CN, -NO 2 , alkyl, alkoxy, benzyl, one or more of -OH, halo, -CN, -NO 2 , benzyl substituted with an alkyl, alkoxy or haloalkyl group, or a 5- or 6-membered heterocyclo ring substituted with a haloalkyl group; R 4 -H, -OH, -CH 3 , -Cl, -F, -N 3 , -OCH 3 , alkenyl, or alkynyl; R 5 -H, -OH, -CH 3 , -Cl, -F, -N 3 , -OCH 3 , alkenyl, or alkynyl; R 10 is -LM, where L is -O-, -O-CH 2 -, -S-, -NH-, -CO-, -SO-, or -CH 2-, M is alkyl, alkyl substituted with one or more -OH or halo groups, alkenyl, alkenyl substituted with one or more -OH or halo groups, alkynyl, alkynyl substituted with one or more -OH or halo groups, alkoxy, alkoxy substituted with one or more -OH or halo groups, cycloalkyl, cycloalkyl, cycloalkyl substituted with one or more -OH or halo groups, aryl, one or more of -OH, halo, -CN, -NO 2 , aryl substituted with alkyl, alkoxy or haloalkyl groups, benzyl, one or more of -OH, halo, -CN, -NO 2 , benzyl substituted with alkyl, alkoxy or haloalkyl groups, heteroaryl, one or more of -OH, halo, -CN, -NO 2 , heteroaryl, heterocyclyl substituted with alkyl, alkoxy or haloalkyl groups, or one or more of -OH, halo, -CN, -NO 2 , heterocyclyl substituted with an alkyl, alkoxy or haloalkyl group.

[0011] In another embodiment, in formula (II): R 8 and R 9 is -H, alkyl, alkyl substituted with one or more -OH or halo groups, alkyl substituted with one or more -OH or halo groups, aryl, one or more -OH, halo, -CN, -NO 2 , aryl substituted with alkyl, alkoxy or haloalkyl groups, benzyl, one or more of -OH, halo, -CN, -NO 2 , benzyl substituted with alkyl, alkoxy or haloalkyl groups, -CH(CH 3 )COOCH(CH 3 ) 2 , -COCH 3 , [ka] [ka] and, [ka] are independently selected from the group consisting of: R 4 is -H, R 5 is -H, and R 10 is -LM, where L is -O- or -O-CH 2 -, M is alkynyl, alkynyl substituted with one or more -OH or halo groups, aryl, one or more -OH, halo, -CN, -NO 2 , aryl substituted with alkyl, alkoxy or haloalkyl groups, benzyl, one or more of -OH, halo, -CN, -NO 2 , benzyl, heteroaryl, or -OH, halo, -CN, -NO substituted with alkyl, alkoxy, or haloalkyl groups; 2 , heteroaryl substituted with an alkyl, alkoxy or haloalkyl group.

[0012] In another embodiment, in formula (II): R 8 and R 9 is a 5- or 6-membered heterocyclic ring or one or more of -OH, halo, -CN, -NO 2 , alkyl, alkoxy, benzyl, one or more of -OH, halo, -CN, -NO 2 , benzyl substituted with an alkyl, alkoxy or haloalkyl group, or a 5- or 6-membered heterocyclo ring substituted with a haloalkyl group; R 4 is -H, R 5 is -H.

[0013] In another embodiment, the compound of formula (II) is isopropyl((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate, Acetic (((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methylphenylphosphoric) anhydride, isopropyl((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)(phenoxy)phosphoryl)-L-alaninate, diphenyl((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonate, 2-((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)-4-(3-chlorophenyl)-1,3,2-dioxaphosphinane-2-oxide, (((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphoryl)bis(oxy))bis(methylene)diisopropyl bis(carbonate), diethyl((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonate, ((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonic acid Phenyl hydrogen ((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonate (4R,5R)-5-(benzyloxy-1,2-dithian-4-yl phenyl((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonate, (4R,5R)-5-(benzyloxy)-1,2-dithian-4-yl P-((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)-N-benzylphosphonamidate, (4R,5R)-5-(prop-2-yn-1-yloxy)-1,2-dithian-4-yl P-((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)-N-benzylphosphonamidate, (4R,5R)-5-(benzyloxy)-1,2-dithian-4-yl(4-fluorophenyl)((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonate, (4R,5R)-5-(benzyloxy)-1,2-dithian-4-yl(4-fluorophenyl)((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonate, (4R,5R)-5-(benzyloxy)-1,2-dithian-4-yl(3-chlorophenyl)((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonate, (4R,5R)-5-(benzyloxy)-1,2-dithian-4-yl o-tolyl((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonate, ((((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphoryl)bis(oxy))bis(methylene)bis(2,2-dimethylpropanoate), acetic (((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methylphosphoric) anhydride, and diethyl (((((2S,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl)thio)methyl)phosphonate. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] Detailed Description of the Invention The present invention provides a compound having formula (I): [ka] X 1 , R 7 , R 4 , R 5 and R 10 is defined above.

[0015] The present invention also provides a compound having the following formula (II): [ka] X 2 , X 3 , X 4 , Y, R 8 and R 9 is defined above.

[0016] In formulae (I) and (II), P can be a chiral or achiral phosphorus atom. The compounds of formulae (I) and (II) can be separated into their individual diastereoisomers, for example, by fractional crystallization from a suitable solvent, such as methanol or ethyl acetate or mixtures thereof, or by chiral chromatography using an optically active stationary phase. Absolute stereochemistry can be determined by X-ray crystallography of crystalline products or crystalline intermediates that are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration.

[0017] Alternatively, any stereoisomer of a compound of general structural formula (I) and (II) may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known absolute configuration.

[0018] If desired, racemic mixtures of compounds can be separated to isolate individual enantiomers. Separation can be carried out by methods well known in the art, for example, by coupling a racemic mixture of a compound with an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods such as fractional crystallization or chromatography. The coupling reaction is often the formation of a salt using an enantiomerically pure acid or base. The diastereomeric derivative can then be converted to a pure enantiomer by cleavage of the added chiral residue. Racemic mixtures of compounds can also be directly separated by chromatographic methods utilizing chiral stationary phases, which are well known in the art.

[0019] Some of the compounds described herein contain olefinic double bonds, and, unless otherwise specified, are meant to include both E and Z geometric isomers.

[0020] Some of the compounds described herein may exist as tautomers with different attachment points of hydrogen with one or more double bond shifts. For example, a ketone and its enol form are keto-enol tautomers. Individual tautomers as well as mixtures thereof are encompassed by the compounds of structural formulas (I) and (II). Examples of tautomers that are intended to be encompassed within the compounds of the present invention are shown below.

[0021] [ka]

[0022] As used herein, the following definitions are applicable.

[0023] "Alkyl", as well as other groups having the prefix "alk", such as alkoxy and alkanoyl, means carbon chains which may be linear or branched, and combinations thereof, unless the carbon chain is otherwise defined. Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec- and tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, and the like. A specific number of carbon atoms is, for example, C 3-10 Where permitted, the term alkyl also includes cycloalkyl groups, and combinations of straight or branched alkyl chains combined with cycloalkyl structures.

[0024] "Haloalkyl" refers to a straight-chain or branched alkyl group in which some or all of the group's hydrogen atoms may be replaced by halogen atoms.

[0025] "Alkenyl" refers to a straight or branched chain alkene of 2 to 20 carbon atoms, or any number within this range. Examples of alkenyl groups include ethenyl, propenyl, butenyl, pentenyl, oleyl, and the like.

[0026] "Alkenyl" refers to a straight or branched chain alkene of 2 to 20 carbon atoms, or any number within this range. Examples of alkenyl groups include ethenyl, propenyl, butenyl, pentenyl, oleyl, and the like.

[0027] "Cycloalkyl" is a subset of "alkyl" and means a saturated carbocyclic ring having a specified number of carbon atoms. Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like. Cycloalkyl groups are generally monocyclic unless otherwise specified. Cycloalkyl groups are saturated unless otherwise specified.

[0028] "Aryl" refers to cyclic aromatic hydrocarbon groups having one to three aromatic rings, including phenyl and naphthyl. The aryl group may be fused to a second or third ring that is a heterocyclo, cycloalkyl, or heteroaryl ring, in which case the point of attachment is on the aryl portion of the ring system.

[0029] "Heteroaryl" refers to an aromatic or partially aromatic heterocycle containing at least one ring heteroatom selected from O, S, and N; thus, heteroaryl includes heteroaryls fused to other types of rings, such as aryls, cycloalkyls, and heterocycles, that are not aromatic. Examples of heteroaryl groups include pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furyl, triazinyl, thienyl, pyrimidyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, dihydrobenzofuranyl, indolinyl, indolinyl, pyridazinyl, indazolyl, isoindolyl, dihydrobenzothienyl, indolizinyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, carbazolyl, benzodioxolyl, quinoxalinyl, purinyl, furazanyl, isobenzylfuranyl, benzimidazolyl, benzofuranyl, benzothienyl, quinolyl, indolyl, isoquinolyl, dibenzofuranyl, and the like.

[0030] "Heterocyclyl" or "heterocyclo ring" refers to a fully saturated or partially unsaturated non-aromatic cyclic group (e.g., a 4- to 7-membered monocyclic, a 7- to 11-membered bicyclic, or a 10- to 16-membered tricyclic ring system) having at least one heteroatom in at least one carbon atom-containing ring. Each ring of a heteroatom-containing heterocyclic group may have 1, 2, 3, or 4 heteroatoms selected from nitrogen, oxygen, and / or sulfur atoms, where the nitrogen and / or sulfur heteroatoms may be optionally oxidized and the nitrogen heteroatom may be optionally quaternized. The heterocyclo ring may have a carbon ring atom replaced with a carbonyl group (C=O), as set forth above for cycloalkyl groups.

[0031] A "halo group" refers to -F, -Cl, -Br, and -I.

[0032] The compounds of the present invention can be prepared from known or readily prepared starting materials according to methods known to those skilled in the art of organic synthesis. Methods useful for preparing compounds of the formula are illustrated in the following examples and outlined in Schemes A, B, and C below. Alternative synthetic routes and analogous structures will be apparent to those skilled in the art of organic synthesis.

[0033] Scheme A illustrates a method useful for preparing nucleoside compounds of formula A4, which correspond to compounds of formula (II). R 1 , R 2 , R 3 and R 6 is independently -H, alkyl, alkenyl, cycloalkyl, unsubstituted or substituted heteroaryl, substituted or substituted aryl; R 4 and R 5 are independently -H, -OH, -CH 3 , -Cl, -F, -N 3 , -OCH 3 , alkenyl or alkynyl.

[0034] [ka]

[0035] Compounds of type A1 can be reacted with A2 to give A3, which can then be followed by TBS deprotection to give compounds of type A4.

[0036] Scheme B illustrates a method useful for preparing nucleoside compounds of formula B4 which correspond to compounds of formula (I).

[0037] In reaction B, R 10 , R 4 and R 5 is R of formula (II) 10 , R 4 and R 5 This is the same definition as

[0038] [ka]

[0039] Compounds of type B1 can be reacted with B2 to give B3, which is then followed by removal of the following protecting groups to give compounds of type B4.

[0040] Scheme C illustrates a method useful for preparing nucleoside compounds of formulas C4 and C5, which correspond to compounds of formula (II).

[0041] In formulas C4 and C5: R 1 , R 2 are independently -H, alkyl, alkenyl, cycloalkyl, unsubstituted or substituted heteroaryl, unsubstituted or substituted aryl, or form a substituted or unsubstituted 5- or 6-membered heterocyclo ring; R 4 and R 5 are independently -H, -OH, -CH 3 , -Cl, -F, -N 3 , -OCH 3 , alkenyl, or alkynyl.

[0042] [ka]

[0043] The C1 complex is TsOCH 2 P(O)OR 1 OR 2 to give C2, then converting Cl to SH as C3, removing the blocking group to give the C4 type complex, and further reacting with R to give the C5 type complex. 1 and R 2 The groups were deprotected.

[0044] General steps: Preparative thin layer chromatography (PTLC) was performed on 20 x 20 cm plates (500 micron thick silica gel). Silica gel chromatography was performed on a Biotage Horizon flash chromatography system.

[0045] 1 H and 31 P NMR spectra were recorded at 400 MHz on a Bruker Ascend® 400 spectrometer at 298° K; chemical shifts are given in parts per million (ppm) referenced to the residual proton signal of the deuterated solvent: CHCl at δ = 7.26 ppm. 3 and CH at δ = 3.30 ppm 3 OH or CH 3 O.D.

[0046] LCMS spectra were obtained on an Agilent Technologies 1260 Infinity or 6120 Quadrupole spectrometer. The LC mobile phase was acetotrile (A) and water (B) with 0.01% formic acid, and the eluent gradient was 5–95% A in 6.0 min, 60–95% A in 5.0 min, 80–100% A in 5.0 min, and 85–100% A in 10 min, using an SBC1850 mm × 4.6 mm × 2.7 μm capillary column.

[0047] Mass spectra (MS) were measured by electrospray ion mass spectrometry (ESI). All temperatures are in degrees Celsius unless otherwise stated.

[0048] Analytical HPLC mass spectrometry conditions: LC1: Column: SB-C18 50mm x 4.6mm x 2.7μm Temperature: 50℃ Eluent: 5:95 v / v acetonitrile / water + 0.01% formic acid / 6 min. Flow rate: 1.5mL / min, injection 5μL Detection: PDA, 200~600nm MS: Mass range 150-750 amu; positive ion electrospray ionization

[0049] LC2: Column: SB-C18 50mm x 4.6mm x 2.7μm Temperature: 50℃ Eluent: 5:95 to 95:5 v / v acetonitrile / water + 0.05% TFA, 3.00 min. Flow rate: 1.5mL / min, injection 5μL Detection: PDA, 200~600nm MS: Mass range 150-750 amu; positive ion electrospray ionization

[0050] LC3: Column: SB-C18 50mm x 4.6mm x 2.7μm Temperature: 50℃ Eluent: 10:90 to 98:2 v / v acetonitrile / water + 0.05% TFA, 3.75 min. Flow rate: 1.0 mL / min, injection 10 μL Detection: PDA, 200~600nm MS: Mass range 150-750 amu; positive ion electrospray ionization

[0051] The following abbreviations are used in the examples, schemes and tables: AcOH = acetic acid, Aq = aqueous, Ark = alkyl, Ar = aryl, Boc = tert-butyloxycarbonyl, br = broad singlet, CH2 Cl 2 = dichloromethane, d = doublet, dd = doublet of doublet, DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene, DCM = dichloromethane, DMA = 4-dimethylaminopyridine, DMF = N,N-dimethylformamide, DMSO = dimethylsulfoxide, EA = ethyl acetate, EDCI = 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, ESI = electrospray ionization, Et = ethyl, Et 3 N = triethylamine, EtOAc = ethyl acetate, EtOH = ethyl alcohol, h = time, HPLC = high performance liquid chromatography, HOAc = acetic acid, LiOH = lithium hydroxide, m = multiplet, Me = methyl, MeCN = acetonitrile, MeOH = methyl alcohol, MgSO 4 = magnesium sulfate, min = minutes, MS = mass spectrometry, NaCl = sodium chloride, NaOH = sodium hydroxide, Na 2 SO4 = sodium sulfate, NMI = N-methylimidazole, NMR = nuclear magnetic resonance spectroscopy, PE = petroleum ether, PG = protecting group, Ph = phenyl, q = quartet, rt = room temperature, s = singlet, t = triplet, TBME = t-butyl dimethyl ether, TFA = trifluoroacetic acid, THF = tetrahydrofuran, Ts = p-toluenesulfonyl (tosyl). EXAMPLES

[0052] The following examples provide illustrations of the conditions used to prepare the compounds of the present invention.The examples provided are not intended to limit the scope of the present invention and should not be interpreted as such.Those skilled in the art of nucleoside and nucleotide synthesis will easily understand that known variations of the conditions and processes of the following preparation procedures can be used to prepare these and other compounds of the present invention.

[0053] Example 1 [ka]

[0054] 2-Amino-9-[2-(5-benzyloxy-[1,2]dithian-4-yloxy)-2-oxo-tetrahydro-2l5-furo[3,2-d][1,3,2]-dioxaphosphinine-6-yl]-1,9-dihydro-purine-6-thione [ka]

[0055] Step 1: Intermediate 2 1 (15.2 g, 26.7 mmol), triphenylmethyl mercaptan (11.1 g, 40.0 mmol) and K in DMF (91 ml) 2 CO 3 A mixture of (7.4 g, 53.3 mmol) was heated at 80° C. for 3 h. The reaction mixture was cooled and poured into cold water. The resulting mixture was extracted twice with EtOAc. The combined organic layers were washed with water, brine and concentrated under reduced pressure. The residue was purified by column chromatography (PE / EtOAc=3 / 1-5 / 3) to give 2 (12.2 g, white amorphous solid, 56.5%).

[0056] 1 H nuclear magnetic resonance (400MHz, DMSO-d 6 )δ 8.69(1H,s), 7.29-7.20(15H,m), 6.34(1H,t,J=6.8Hz), 5.36-5.33(1H,m), 4.28~4.21(2H,m), 4 .15-4.08(1H,m), 3.12-3.05(1H,m), 2.58-2.52(1H,m), 2.06(3H,s), 1.96(3H,s), 1.30(18H,s).

[0057] Step 2: Intermediate 3 A solution of 2 (12.2 g, 15.1 mmol) in THF (125 mL) was diluted with LiOH H in water (25 mL). 2 A solution of 2,4-dichlorophenyl 2,6-dichlorophenyl 2,7-dichlorophenyl 2,8 ... 2 SO 4The mixture was dried at 40° C. and concentrated under reduced pressure. The residue was suspended in tert-butyl methyl ether (80 mL) and stirred vigorously for 30 min. The slurry was filtered and washed with tert-butyl methyl ether (40 mL). The filter cake was collected and dried under reduced pressure to give 3 (9.4 g, white solid, 86.2%).

[0058] 1 H nuclear magnetic resonance (400MHz, DMSO-d 6 )δ 8.68(1H,s), 7.32-7.19(15H,m), 6.29(1H,t,J=6.8Hz), 5.32(1H,d,J=3.6Hz), 4.92(1H,brs), 4.41-4 .35(1H,m), 3.86-3.82(1H,m), 3.59-3.43(2H,m), 2.70-2.64(1H,m), 2.32-2.26(1H,m), 1.30(18H,s).

[0059] Step 3: Intermediate 5 To the reaction solution of 3 above, 4 (3369 mg, 4.64 mmol) and DBU (1882 mg, 12.4 mmol) were added. The reaction was stirred at room temperature for 2 h and then heated at 44° C. overnight. Most of the solvent was removed by evaporation. The residue was directly purified by column chromatography (PE / EtOAc=3 / 2 to 4 / 5) to give 5 (520 mg, yellowish amorphous solid, 16.6% two steps).

[0060] Step 4: Final compound 6 To a solution of 5 (790 mg, 0.781 mmol) and triethylsilane (454 mg, 3.9 mmol) in DCM (10 mL) was added TFA (8 mL). The reaction was stirred at room temperature for 2 h and then concentrated under reduced pressure. The residue was azeotroped twice with DCM. The resulting residue was purified by column chromatography (DCM / MeOH=50 / 1 to 33 / 1 to 25 / 1) to give the crude product. The crude product was suspended in MeOH (4 mL) and stirred for 30 min. The slurry was filtered and washed with MeOH (2 mL). The filter cake was collected and dried under reduced pressure to give 6 (101.4 mg, white solid, 22.8%).

[0061] LCMS: C 21 H 24 N 5 O 6 P.S. 3 In this case, the calculated value is 569.1, and the measured value is 570.2 [M+H]. + . 1 H NMR (400 MHz, DMSO-d 6 )δ12.03,12.01(1H,s), 8.20,8.20(1H,s, ratio 1:2), 7.39-7.11(5H,m), 6.87,6.82(1H,brs), 6.27-6.20(1H,m), 5.06-4.99, 4.9 2-4.85(1H,m), 4.73-4.26(5H,m), 4.02-3.93(1H,m), 3.78-3.72(1H,m), 3.61-3.42(2H,m), 3.26-3.17(1H,m), 3.01-2.94(1H, m),2.87-2.59,2.35-2.28(2H,m).

[0062] Examples 2 to 13 The compounds in Table 1 can be prepared by the same methods described in Example 1.

[0063] [Table 1-1] [Table 1-2] [Table 1-3]

[0064] Example 13: [ka]

[0065] 2-{[5-(2-amino-6-mercapto-purin-9-yl)-3-hydroxy-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester

[0066] [ka]

[0067] Step 1: 3',5'-O-di-tert-butyldimethylsilyl-2'-deoxythioguanosine (1): To a solution of 2´-deoxythioguanosine (2.3 g, 8.13 mmol) and imidazole (3.65 g, 53.66 mmol) in 15 ml of anhydrous DMF was added 3.90 g (26.0 mmol) of tert-butyldimethylsilyl chloride (TBDMS-Cl). The reaction mixture was stirred at room temperature for 20 h. The resulting mixture was poured into water (100 mL). The precipitate was collected by filtration, rinsed with a cold mixture of ethanol and water (1:2), and dried under reduced pressure to give 3.6 g of the title compound 1 as a grey solid (85% yield).

[0068] LC-MS: (ES, m / z): [M+H] + =512. 1 H NMR(400MHz,DMSO) δ 12.01(s,1H), 8.11(s,1H), 6.87(s,2H), 6.14(t,J=6.5Hz,1H), 4.52(s,1H), 3.8 5(s,1H), 3.79-3.66(m,2H), 2.73-2.63(m,1H), 2.29(dd,J=7.5,3.9Hz,1H), 0.91 (d,J=4.6Hz,18H), 0.13(s,6H), 0.08(s,6H).

[0069] Step 2: 3'-O-tert-butyldimethylsilyl-5'-hydroxy-2'-deoxythioguanosine (2): To a stirred solution of 1 (1.05 g, 1.96 mmol) in tetrahydrofuran (40 mL) was added TFA-H 2 HO (10 mL, 1:1 v / v) was added at 0 °C. The reaction mixture was stirred at 0 °C for 2 h. Saturated sodium bicarbonate solution was added to neutralize to pH ~ 8. The solid was filtered, washed with cold water, and dried under reduced pressure to give the product 2 (0.67 g, 84% yield) as a light grey powder.

[0070] LC-MS: (ES, m / z): [M+H] + =398. 1 H NMR(400MHz,DMSO) δ 11.95(s,1H), 8.08(s,1H), 6.67(s,2H), 6.10(t, J=6.7Hz,1H), 5.07(s,1H), 4.51 (s,1H), 3.81 (s,1H), 3.51 (d,J=8.6Hz, 2H), 2.70-2.59(m,1H), 2.20(d,J=9.0Hz, 1H), 0.89(s,9H), 0.10(s,6H).

[0071] Step 3: Intermediate 4: To a stirred solution of protected 2´-deoxythioguanosine (2, 0.81 g, 2.05 mmol) in dry THF-NMP (20 mL, 1:1 v / v) was added dropwise a 1.0 M solution of tert-butylmagnesium chloride in THF (4.5 mL, 4.51 mmol) at room temperature. The white suspension was stirred at this temperature for 30 min and a THF solution of commercially available phosphate salt 3 (1.1 g, 2.45 mmol) was added. The mixture was stirred at this temperature overnight. Saturated NH 4 The reaction was quenched with Cl(aq) and extracted with ethyl acetate. The organic layers were combined, washed with brine and anhydrous Na 2 SO 4. The solvent was removed under reduced pressure and the crude product was purified by column chromatography eluting with dichloromethane / methanol (20:1) to give the title compound 4 (0.75 g, 55% yield).

[0072] LC-MS: (ES, m / z): [M+H] + =667. 1H NMR(400MHz,DMSO) δ 11.98(s,1H), 8.10(s,1H), 7.36(t,J=7.8Hz,2H), 7.18(dd,J=15.3,7.7Hz,3H), 6.82(br,2H), 6.13(t,J=6.9Hz,1H), 6.06(dd,J=12.8,10 .3Hz,1H), 4.83(dt,J=12.5, 6.3Hz,1H), 4.52(s,1H), 4.23-4.14(m,1H), 4.07-3.95(m,2H), 3.77(dd,J=17.2,10.0Hz,1H), 3.17(d,J=5.1 Hz,1H), 2.75-2.61(m,1H), 2.25(dd,J=12.0,4.8Hz,1H), 1.20(d,J=7.0Hz,3H), 1.16-1.08(m,6H), 0.87(s,9H), 0.08(s,6H). 31 P NMR (400 MHz, DMSO) δ 3.70.

[0073] Step 4: 2-{[5-(2-amino-6-mercapto-purin-9-yl)-3-hydroxy-tetrahydro-furan-2-ylmethoxy]-phenoxy-phosphorylamino}-propionic acid isopropyl ester (5) 20 mL of fresh hydrogen chloride in methanol (prepared from the addition of 5 mL of acetyl chloride to 500 mL of dry methanol) was added to the corresponding phosphoramidate 4 at room temperature. The reaction was stirred for 40 h and then quenched with saturated aqueous sodium acetate. The resulting mixture was extracted with dichloromethane. The organic layers were combined, washed with brine, and purified by filtration with anhydrous NaCl. 2 SO 4 The solvent was removed under reduced pressure and the crude product was purified by Prep-TLC to give the final product 5 (40 mg, 24% yield).

[0074] LC-MS: (ES, m / z): [M+H] + =553. 1H NMR(400MHz,DMSO) δ 11.96(s,1H), 8.04(s,1H), 7.36(t,J=7.4Hz,2H), 7.18(dd,J=16.6,7.6Hz,3H), 6.81 (s,2H), 6.14(t,J=6.4Hz,1H), 6.00(t,J=11.5Hz,1H), 5.44(d,J=2.8Hz,1H), 4.89-4.77 (m,1H), 4.38(s,1H), 4.19(d,J=4.5Hz,1H), 4.03(dd,J=20.3,9.5Hz,2H), 3.78(d,J=7.1 Hz,1H), 2.56(d,J=6.6Hz,1H), 2.26(s,1H), 1.20(d,J=6.7Hz,3H), 1.13(d,J=3.3Hz,6H). 31 P NMR (400 MHz, DMSO) δ 3.80.

[0075] Example 14 [ka]

[0076] ((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonic acid

[0077] [ka]

[0078] Step 1: Diethyl ((((2R,3S,5R)-5-(2-amino-6-chloro-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)tetrahydrofuran-2-yl)methoxy)methyl)phosphonate (2) 1 (685 mg, 1.71 mmol), (diethoxyphosphoryl)methyl 4-methylbenzenesulfonate (1.10 g, 3.43 mmol), t-BuO in dry DMSO (20 ml). 2A mixture of magnesium (1.16 g, 6.84 mmol) was stirred at 70° C. for 3 h under a positive argon atmosphere. After cooling, the mixture was poured into cold ammonium chloride solution (50 mL). The mixture was extracted with ethyl acetate (3×50 mL). The organic phases were combined, washed with brine (100 mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under vacuum. The crude product was purified by column chromatography eluting with dichloromethane / methanol (50:1) to give 2 (660 mg, 69% yield).

[0079] LC-MS: (ES, m / z): [m+H] + =551.1. 1 H NMR (400 MHz, CDCl 3 ) δ 8.04(s,1H), 6.27(dd,J=7.4,6.3Hz,1H), 5.44(s,2H), 4.64-4.55(m,1H), 4.25-4.11 (m,4H), 4.06(dd,J=6.4,3.6Hz,1H), 3.94(dd,J=10.5,4.2Hz,1H), 3.90-3.78(m,2H), 3.73(dd,J=10.5,3.6Hz,1H), 2.81 (ddd,J=13.2,7.7,5.7Hz,1H), 2.28(ddd,J=13.1,6.0,2.8Hz,1H), 1.33(dt,J=9.5,7.1 Hz,6H), 0.90(s,9H), 0.10(d,J=6.1 Hz,6H). 31 P NMR (400 MHz, CDCl 3 ): δ 20.86.

[0080] Step 2: Diethyl ((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-((tert-butyldimethylsilyl)oxy)tetrahydrofuran-2-yl)methoxy)methyl)phosphonate (3) To a mixture of 2 (660 mg, 1.20 mmol) in dry DMF (10 mL) was added anhydrous NaHS (289 mg, 7.20 mmol) at 0° C. and the mixture was stirred for 2 h. It was then neutralized with 10% aqueous AcOH (2 mL). The resulting precipitate was filtered and dried under vacuum to give the desired product 3 (320 mg, 58.7% yield).

[0081] LC-MS: (ES, m / z): [M+H] + =548.1. 1 H NMR(400MHz,DMSO) δ 11.95(s,1H), 8.06(s,1H), 6.82(s,2H), 6.12(t,J=6.9Hz,1H), 4.48(s,1H), 4.11-3.98(m,4H), 3.93(s,1H), 3.87(d,J=8.1 Hz,2H), 3.68(ddd,J=45.8,10.3,4.7Hz,2H), 2.71-2.62(m,1H), 2.27-2.19(m,1H), 1.23(td,J=6.9,4.1 Hz,6H), 0.88(s,9H), 0.10(s,6H). 31 P NMR (400MHz, DMSO): δ 21.23.

[0082] Step 3: Diethyl ((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonate (4) To a solution of 3 (140 mg, 0.256 mmol) in dry THF (10 mL) was added TBAF (0.38 mL, 0.383 mmol) dropwise at ambient temperature and the mixture was stirred for 3 h. The resulting mixture was concentrated in vacuo at ambient temperature and purified by Prep-HPLC to give 4 (70 mg).

[0083] LC-MS: (ES, m / z): [M+H] + =434.1. 1H NMR(400MHz,DMSO) δ 7.64(d,J=4.7Hz,1H), 6.12(dd,J=7.9,6.2Hz, 1H), 5.31 (s,1H), 5.23(s,2H), 4.37-4.25(m,1H), 4.10-3.97(m,4H), 3.87(dd,J=9.8,5.3Hz,3H), 3.74(dd,J=10.5,4.5Hz,1H ), 3.63(dd,J=10.5,5.2Hz,1H), 2.64-2.54(m,1H), 2.12(ddd,J=13.0,6.0,2.6Hz,1H), 1.23(td,J=7.1,3.7Hz,6H). 31 P NMR (400MHz, DMSO): δ 21.32.

[0084] Step 4: ((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonic acid (5) To a mixture of 4 (50 mg, 0.115 mmol) and 2,6-lutidine (308 mg, 2.88 mmol) in dry DCM (5 mL) was added TMSBr (352 mg, 2.31 mmol) dropwise at ambient temperature and the mixture was stirred overnight. The resulting mixture was concentrated in vacuo and purified by Prep-HPLC to give 5 (5.0 mg, 10.2% yield).

[0085] LC-MS: (ES, M / z):[MH] - =376.1, 1 H NMR(400MHz,DMSO) δ 11.92(s,1H), 8.10(s,1H), 6.83(s,2H), 6.17-6.09(m,1H), 4.40-4.32(m,1H), 3.93(d,J=2.3Hz,1H), 3.75(dd,J=10.5,4.5Hz,1H), 3.59(d,J=8.5Hz,3H), 2.63(dd,J=13.3,7.8Hz,1H), 2.24-2.16(m,1H). 31 P NMR (400MHz, DMSO): δ 16.39.

[0086] Examples 15 to 32 The compounds in Table 2 can be prepared by the same methods described in Examples 13 and 14.

[0087] [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4]

[0088] Example 32 The compounds of Examples 1-31 are tested in a xenograft animal model using A549 cells at an oral dose of 5mg / kg for 21 days. 6-thio-dG is used as a control. The compounds of Examples 1-31 show good efficacy against tumor growth. More importantly, these compounds are much less toxic than 6-thio-dG. These compounds can be used to treat various diseases such as cancer and viral infections.

[0089] Although the present invention has been described and illustrated with reference to specific embodiments thereof, those skilled in the art will understand that various changes, modifications, and substitutions can be made without departing from the spirit and scope of the present invention. For example, effective doses other than the preferred doses above may be applicable as a result of changes in the responsiveness of humans treated for cancer or otherwise. Similarly, the pharmacological response observed may vary according to and depending on the specific active compound selected, or whether or not a pharmaceutical carrier is present, as well as the type of formulation and mode of administration used, and such expected variations or differences in results are contemplated according to the purpose and practice of the present invention. Accordingly, it is intended that the present invention be limited only by the scope of the following claims, and that such claims be interpreted as broadly as is reasonable.

Claims

1. A compound having the following formula (I): or a tautomer thereof: 【Chemistry 1】 [Where: X 1 is -O-, R 7 teeth, 【Chemistry 2】 or 【Chemistry 3】 and R 4 is -H, R 5 is -H, R 10 is -LM, where L is -O- or -O-CH 2 -, M is alkynyl, alkynyl substituted with one or more -OH or halo groups, aryl, one or more -OH, halo, -CN, -NO 2 , aryl substituted with alkyl, alkoxy or haloalkyl groups, benzyl, one or more of -OH, halo, -CN, -NO 2 , benzyl substituted with alkyl, alkoxy or haloalkyl groups, heterocyclyl, or one or more of -OH, halo, -CN, -NO 2 , heterocyclyl substituted with an alkyl, alkoxy or haloalkyl group.

2. The compound is 2-amino-9-((2S,4aR,6R,7aS)-2-(((4R,5R)-5-(benzyloxy)-1,2-dithian-4-yl)oxy)-2-oxidetetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-6-yl)-1,9-dihydro-6H-purine-6-thione, 2-amino-9-((2S,4aR,6R,7aS)-2-(((4S,5S)-5-(benzyloxy)-1,2-dithian-4-yl)oxy)-2-oxidetetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-6-yl)-1,9-dihydro-6H-purine-6-thione, 2-amino-9-((2R,4aR,6R,7aS)-2-(((4S,5S)-5-(benzyloxy)-1,2-dithian-4-yl)oxy)-2-oxidetetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-6-yl)-1,9-dihydro-6H-purine-6-thione, 2-amino-9-((2R,4aR,6R,7aS)-2-(((4R,5R)-5-(benzyloxy)-1,2-dithian-4-yl)oxy)-2-oxidetetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-6-yl)-1,9-dihydro-6H-purine-6-thione, S-(3-(((2R,4aR,6R,7aS)-6-(2-amino-6-thioxo-1,6-dihydro-9H-purin-9-yl)-2-oxidetetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-2-yl)oxy)propyl)2,2-dimethyl-3-propoxypropanethioate, S-(3-(((2S,4aR,6R,7aS)-6-(2-amino-6-thioxo-1,6-dihydro-9H-purin-9-yl)-2-oxidetetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-2-yl)oxy)propyl)2,2-dimethyl-3-propoxypropanethioate, 2-amino-9-((2S,4aR,6R,7aS)-2-(((4R,5R)-5-(benzyloxy)-1,2-dithian-4-yl)oxy)-2-sulfidotetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-6-yl)-1,9-dihydro-6H-purine-6-thione, 2-amino-9-((2R,4aR,6R,7aS)-2-(((4R,5R)-5-((2-methylbenzyl)oxy)-1,2-dithian-4-yl)oxy)-2-oxidetetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-6-yl)-1,9-dihydro-6H-purine-6-thione, 2-amino-9-((2R,4aR,6R,7aS)-2-oxido-2-(((4R,5R)-5-(propyl-2-yn-1-yloxy)-1,2-dithian-4-yl)oxy)tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-6-yl)-1,9-dihydro-6H-purine-6-thione, 2-amino-9-((2R,4aR,6R,7aS)-2-(((4R,5R)-5-methoxy-1,2-dithian-4-yl)oxy)-2-oxidetetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-6-yl)-1,9-dihydro-6H-purine-6-thione, and 2-amino-9-((2R,4aR,6R,7aS)-2-oxido-2-(((4R,5R)-5-(pyridin-4-ylmethoxy)-1,2-dithian-4-yl)oxy)tetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinine-6-yl)-1,9-dihydro-6H-purine-6-thione.

3. A compound having the following formula (II): or a tautomer thereof: 【Chemistry 4】 [Where: X 2 is —O— or —NH—, X 3 is —O— or —NH—, X 4 is -CH 2 - or nil, Y is -O-, -S-, or -SO 2 - and R 8 and R 9 is an alkyl group, an alkyl group substituted with one or more -OH or halo groups, an aryl group, one or more -OH, halo, -CN, -NO 2 , aryl substituted with alkyl, alkoxy or haloalkyl groups, benzyl, one or more of -OH, halo, -CN, -NO 2 , benzyl substituted with alkyl, alkoxy or haloalkyl groups, —CH(CH 3 ) COOCH (CH 3 ) 2 , -COCH3, 【Chemistry 5】 【Chemistry 6】 and, 【Chemistry 7】 or R 8 and R 9 is a 5- or 6-membered heterocyclic ring, or one or more of -OH, halo, -CN, -NO 2 , alkyl, alkoxy, benzyl, one or more of -OH, halo, -CN, -NO 2 , benzyl substituted with an alkyl, alkoxy or haloalkyl group, or a 5- or 6-membered heterocyclic ring substituted with a haloalkyl group; R 4 is -H, R 5 is -H, R 10 is -LM, where L is -O- or -O-CH 2 -, M is alkynyl, alkynyl substituted with one or more -OH or halo groups, aryl, one or more -OH, halo, -CN, -NO 2 , aryl substituted with alkyl, alkoxy or haloalkyl groups, benzyl, one or more of -OH, halo, -CN, -NO 2 , benzyl substituted with alkyl, alkoxy or haloalkyl groups, heteroaryl, or one or more of -OH, halo, -CN, -NO 2 , heteroaryl substituted with alkyl, alkoxy or haloalkyl groups.

4. The compound is isopropyl((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate, Acetic (((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methylphenylphosphoric) anhydride, isopropyl(((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)(phenoxy)phosphoryl)-L-alaninate, diphenyl((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonate, 2-((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)-4-(3-chlorophenyl)-1,3,2-dioxaphosphinane 2-oxide, ((((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphoryl)bis(oxy))bis(methylene)diisopropyl bis(carbonate), diethyl((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonate, ((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonic acid, phenylhydrogen((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonate, (4R,5R)-5-(benzyloxy)-1,2-dithian-4-ylphenyl((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonate, (4R,5R)-5-(benzyloxy)-1,2-dithian-4-yl P-((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)-N-benzylphosphonamidate, (4R,5R)-5-(propyl-2-yn-1-yloxy)-1,2-dithian-4-yl P-((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)-N-benzylphosphonamidate, (4R,5R)-5-(benzyloxy)-1,2-dithian-4-yl(4-fluorophenyl)(((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonate, (4R,5R)-5-(benzyloxy)-1,2-dithian-4-yl(4-fluorophenyl)((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonate, (4R,5R)-5-(benzyloxy)-1,2-dithian-4-yl(3-chlorophenyl)((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonate, (4R,5R)-5-(benzyloxy)-1,2-dithian-4-yl o-tolyl((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphonate, ((((((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)methyl)phosphoryl)bis(oxy))bis(methylene)bis(2,2-dimethylpropanoate), acetic (((2R,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methylphosphoric) anhydride, and 4. The compound of claim 3 selected from the group consisting of diethyl (((((2S,3S,5R)-5-(2-amino-6-mercapto-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methyl)thio)methyl)phosphonate.

Citation Information

Patent Citations

  • Methods and compositions for treating hepatitis c virus

    WO2001090121A2

  • Methods and compositions for treating flaviviruses and pestiviruses

    WO2001092282A2

  • 3', 5' - cyclic nucleoside analogues for treatment of hcv

    WO2007027248A2

  • Nucleoside cyclicphosphates

    WO2009152095A2

  • Nucleotide and nucleoside therapeutic compositions and uses related thereto

    WO2014124430A1